Colistin-Resistant <i>Klebsiella pneumoniae</i>: Report of a Cluster of 24 Cases from a New Oncology Center in Eastern India

Goel, Gaurav; Hmar, Lalawmpuia; De, Maitrayee Sarkar; Bhattacharya, Sanjay; Chandy, Mammen

doi:10.1086/677170

Cited by 44 publications

(46 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Less resistance was noticed for amikacin 42% and gentamicin (40%). This on contrary to previous results reporting poor sensitivity to aminoglycosides [23,33]. This difference in susceptibility may reflect the difference of antibiotics policy among different health care settings in different geographical regions.…”

Section: Resultscontrasting

confidence: 99%

“…In the present study, 50 colistin resistant isolates during 36 months had been collected in which the most common sources were urine (46%), blood (30%) and wounds (24%).Similar result was obtained by previous study [22][23][24].…”

Section: Discussionsupporting

confidence: 88%

“…Previous reports were online with these results as K. Pneumoniae, E. coli A. baumannii and Enterobacter cloacae were frequently associated with colistin resistance [23][24][25].…”

Section: Discussionmentioning

confidence: 55%

See 2 more Smart Citations

Molecular study of colistin resistant clinical isolates of Enterobacteriaceae species

Zaki¹,

ElKheir²,

Mofreh³

2018

J Clin Mol Med

View full text Add to dashboard Cite

show abstract

Section: Resultscontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 88%

See 1 more Smart Citation

Molecular study of colistin resistant clinical isolates of Enterobacteriaceae species

Zaki¹,

ElKheir²,

Mofreh³

2018

J Clin Mol Med

View full text Add to dashboard Cite

show abstract

“…Phenotypic studies revealed that the isolates (24/24) were resistant to colistin by disk diffusion and micro-broth dilution method. There are reports on the prevalence of colistin-resistant Klebsiella pneumoniae in eastern India (19). In the previous study by Poudyal et al, conducted on 22 multi-drug resistant Klebsiella pneumoniae, of which 6 isolates were colistin resistant with MIC of ≥ 32 µg/mL (20).…”

Section: Discussionmentioning

confidence: 99%

Colistin-Resistant Klebsiella pneumoniae: Prevalence of Integrons and Synergistic Out Turn for Colistin-Meropenem

Manohar

Shanthini

Pandey

et al. 2018

Arch Clin Infect Dis

View full text Add to dashboard Cite

Background: Klebsiella pneumoniae has the potential to disseminate at speed among the hospital environment, hence included as a major nosocomial pathogen causes of severe infections. This work mainly focused on finding out the prevalence of different classed of integrons in colistin-resistant Klebsiellapneumoniae and to analyze the efficacy of colistin-meropenem in combination. Methods: For this cross-sectional study, random non-biased sampling technique was followed and non-repetitive, Kleb-

show abstract

“…61,62 In one oncology center in India, colistinresistant CRKP have emerged, leaving essentially no therapeutic options for patients infected by these pathogens. 63 CRE are also emerging pathogens in HSCT recipients, particularly after allogeneic transplantation. Italian transplant centers reported that the post-transplant incidence of CRKP infection in allogeneic HSCT recipients increased from 0.4% in 2010 to 2.9% in 2013.…”

Section: Cre In Patients With Hematologic Malignancies and Haematopoimentioning

confidence: 99%

Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies

2016

View full text Add to dashboard Cite

Carbapenem-resistant Enterobacteriaceae (CRE) are a major global public health concern and pose a serious threat to immunocompromised hosts, particularly patients with hematologic malignancies and solid organ (SOT) and stem cell transplant recipients. In endemic areas, carbapenem-resistant Klebsiella pneumoniae infections occur in 1-18% of SOT recipients, and patients with hematologic malignancies represent 16-24% of all patients with CRE bacteremia. Mortality rates approaching 60% have been reported in these patient populations. Early diagnosis and rapid initiation of targeted therapy is critical in the management of immunocompromised hosts with CRE infections, as recommended empiric regimens are not active against CRE. Therapeutic options are limited by antibiotic-associated toxicities, interactions with immunosuppressive agents, and paucity of antibiotic options currently available. Prevention of CRE infection in these patients requires a multidisciplinary approach involving hospital epidemiology and antimicrobial stewardship. Large, multicenter studies are needed to develop risk-stratification tools to assist in guiding the management of these individuals.

show abstract

Colistin-Resistant Klebsiella pneumoniae: Report of a Cluster of 24 Cases from a New Oncology Center in Eastern India

Cited by 44 publications

References 10 publications

Molecular study of colistin resistant clinical isolates of Enterobacteriaceae species

Molecular study of colistin resistant clinical isolates of Enterobacteriaceae species

Colistin-Resistant Klebsiella pneumoniae: Prevalence of Integrons and Synergistic Out Turn for Colistin-Meropenem

Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies

Contact Info

Product

Resources

About